Senior Correspondent, London
Ben's Feed
Aug 17, 2014

Extreme medicine: The search for new antibiotics

NORWICH, England, Aug 17 (Reuters) – Pampering leafcutter
ants with fragrant rose petals and fresh oranges may seem an
unlikely way to rescue modern medicine, but scientists at a lab
in eastern England think it’s well worth trying.

As the world cries out for new antibiotics, researchers at
the John Innes Centre (JIC) in Norwich are also taking a bet on
bacteria extracted from the stomachs of giant stick insects and
cinnabar caterpillars with a taste for highly toxic plants.

Aug 15, 2014
Aug 15, 2014
Aug 15, 2014
Aug 15, 2014
Aug 15, 2014
Aug 14, 2014

UK cost body backs pricey Gilead hepatitis pill for some patients

LONDON, Aug 15 (Reuters) – Gilead Sciences’
expensive new hepatitis C pill has been endorsed for use in
certain patients by Britain’s healthcare cost-effectiveness
watchdog, after the U.S. firm provided more information.

The National Institute for Health and Care Excellence (NICE)
had told Gilead in June to come back with more data to support
the use of Sovaldi, a drug whose sky-high U.S. price of $1,000
per pill has sparked fierce debate over costly modern medicines.

Aug 13, 2014
Aug 13, 2014
Aug 12, 2014

WHO hopes for more Ebola drug doses, vaccine progress by end of year

LONDON (Reuters) – World Health Organization experts fighting the world’s worst outbreak of Ebola hope for improved supplies of experimental treatments and progress with a vaccine by the end of the year.

That may come too late to put an end to the current epidemic, which is more likely to be stopped by standard infection control measures, but it offers hope for the next inevitable outbreak.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben